Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HG004 gene therapy in RPE65 mutation-associated Leber congenital amaurosis type 2
CTR20232920Phase 2Active
- Sponsor
- HuidaGene Therapeutics
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of HG004 in Leber congenital amaurosis (LCA), sponsored by HuidaGene Therapeutics. Started Oct 2023; status: active.
02
Drugs
HG004
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on CTR20232920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232920.